Novartis To Spin Off $9.6B Sandoz Generic Drugs Biz
By Ashish Sareen ( August 25, 2022, 12:59 PM BST) -- Swiss-American pharmaceuticals giant Novartis AG said Thursday that it plans to separate its Sandoz generic drugs division from its core business of developing innovative medicines to form a standalone publicly traded company through a 100% spinoff....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.